Top Markets
#1 Seeker Seeker +136.83%
#2 AI XOVIA AI XOVIA +101.43%
#3 Helium Helium +75.99%
#4 MowCat MowCat +69.58%
#5 Pons Pons +42.35%
#6 UnifAI Network UnifAI Network +35.30%
#7 Zora Zora +30.19%
#8 Bounce Bounce +23.42%
#9 Zylo Ecosystem Zylo Ecosystem +20.57%
#10 TENDIES TENDIES +17.54%
Coin of the day
Seeker Seeker
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Nxera Pharma Co., Ltd. Nxera Pharma Co., Ltd.

Nxera Pharma Co., Ltd.

4565
Rang in aandelen #11675
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a... Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
Aandeelprijs
$7.32
Laatst gesynchroniseerd: 2026-08-28
Marktkapitalisatie
$671.50M
Verandering (1 dag)
1.08%
Verandering (1 jaar)
16.38%
Land
JP
Handel Nxera Pharma Co., Ltd. (4565)

Categorie

Healthcare
Dividendgeschiedenis van Nxera Pharma Co., Ltd. (4565)
Nxera Pharma Co., Ltd. (aandelsymbool: 4565) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Nxera Pharma Co., Ltd. (4565) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH